EGFR a Potential Target in Muscle-Invasive Bladder Cancer With Basal-Like Phenotype

Get Permission

As reported by Rebouissou and colleagues in Science Translational Medicine, a subset of muscle-invasive bladder cancers that present with a basal-like phenotype is associated with poorer survival, EGFR pathway activation, and sensitivity to EGFR inhibition.

Assessment of data from 383 tumors revealed that 23.5% displayed a basal-like phenotype characterized by expression of epithelial basal cell markers and shorter survival. These basal-like tumors exhibited activation of the EGFR pathway associated with frequent EGFR gains and activation of an EGFR autocrine loop. The tumor cells were found to be sensitive to anti-EGFR therapy using both a 40-gene expression classifier derived from human tumors to identify bladder cancer cell lines and a mouse model of chemically induced bladder cancer corresponding to human basal-like bladder cancer.

The authors concluded, “Our findings provide preclinical proof of concept that anti-EGFR therapy can be used to target a subset of particularly aggressive [muscle-invasive bladder cancer] tumors expressing basal cell markers and provide diagnostic tools for identifying these tumors.” ■

Rebouissou S, et al: Sci Transl Med 6:244ra91, 2014.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.